Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TSEM -5.5%, HSIC -3.1%, HIVE -1%, TSN -1%
Other news:
- ACRS -83.2% (Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update)
- VERV -35.9% (Interim Data for VERVE-101)
- CREV -16% (provides provides share count and cash position ahead of meetings with investors)
- ALNY -5% (Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran)
- MLYS -2% (Further Defines Endotype-Specific Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023)
- JRVR -2% (files to delay its 10-Q; requires additional time to complete its procedures relating to its quarter-end financial reporting processes)
- AL -1.8% (announces delivery of first of nine new Airbus A321-200neo Aircraft to ITA Airways)
- MU -0.9% (Barron's out cautious on MU)
Analyst comments:
- PGRE -3.4% (downgraded to Underperform from Neutral at BofA Securities)
- HPP -3.2% (downgraded to Underperform from Neutral at BofA Securities)
- CCAP -1.9% (downgraded to Equal Weight from Overweight at Wells Fargo)
- HIW -1% (downgraded to Neutral from Buy at BofA Securities)
- BBDC -0.9% (downgraded to Equal Weight from Overweight at Wells Fargo)